Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPI2MA)

• Drug Name: WO2012007375C7 Drug Info
• Synonyms: GTPL8085; BDBM50040727

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 58056092
  TTD Drug ID: DMPI2MA

Molecule-Related Drug Atlas

Drug(s) Targeting Renal carcinoma antigen NY-REN-64 (IRAK-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-5718	DMRKU0L	Rheumatoid arthritis	FA20	Phase 2	[4]
Zabedosertib	DMEZGWP	Atopic dermatitis	EA80	Phase 2	[5]
CA-4948	DMWV8C6	Lymphoma	2A80-2A86	Phase 1	[6]
BAY1834845	DM8V62T	Psoriasis vulgaris	EA90	Phase 1	[7]
AZD6793	DM5GRZV	Inflammation	1A00-CA43.1	Phase 1	[8]
SAR444656	DMIF2OL	Atopic dermatitis	EA80	Phase 1	[9]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1	DM6TB4Z	N. A.	N. A.	Patented	[10]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2	DMFUNH4	N. A.	N. A.	Patented	[10]
Indazoletriazolephenyl derivative 1	DMHJDU6	N. A.	N. A.	Patented	[10]
Indazoletriazolephenyl derivative 2	DMWZLK6	N. A.	N. A.	Patented	[10]

Drug(s) Targeting IL-1 receptor-associated kinase 1 (IRAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrazolopyrimidine and thienopyrimidine amide derivative 1	DM6TB4Z	N. A.	N. A.	Patented	[10]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2	DMFUNH4	N. A.	N. A.	Patented	[10]
Indazoletriazolephenyl derivative 1	DMHJDU6	N. A.	N. A.	Patented	[10]
Indazoletriazolephenyl derivative 2	DMWZLK6	N. A.	N. A.	Patented	[10]
WO2012007375C1	DMOZATX	Discovery agent	N.A.	Investigative	[2]
IRAK-1/4 inhibitor	DMOQBGP	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
IL-1 receptor-associated kinase 1 (IRAK1)	TTXAJWN	IRAK1_HUMAN	Inhibitor	[2]
Renal carcinoma antigen NY-REN-64 (IRAK-4)	TTKFVXR	IRAK4_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8085).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045).
• [4] IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
• [5] Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of AstraZeneca
• [9] Clinical pipeline report, company report or official report of Sanofi
• [10] Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.
• [11] Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.